The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...

CFO Shawn Vadala reported Q4 sales of $1.045 billion, representing a 12% increase in both local currency and U.S. dollars. Adjusted operating profit rose 25%, with a margin of 33.7%, up 360 basis ...

Q4 2024 . Management View. Labcorp reported revenue of $3.3 billion for Q4 2024, an increase of 10% year-over-year, with Di ...

Hello, and welcome, everyone, to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky, and I'll be your operator today. (Operator Instructions) I will now hand over to your host, Head of ...

The locus coeruleus is emerging as a major new area of research interest, with many important functions such as regulating ...

Sharps (NASDAQ: STSS) , an innovative medical device and Pharmaceutical packaging company offering patented, best-in-class syringe products, has announced the closing of its firm commitment ...

Rachel Vatnsdal Olson; Analyst; JPMorgan Chase & Co ...

Premature birth and low birth weight disrupt kidney development substantially, which leads to an increased risk of acute kidney injury, chronic kidney disease and hypertension. Broader awareness ...

Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing ...

Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the pricing ...

A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...